Soluble vascular endothelial (VE) cadherin and autoantibodies to VE-cadherin in rheumatoid arthritis patients treated with etanercept or adalimumab
- 1 December 2017
- journal article
- research article
- Published by Elsevier in Joint Bone Spine
- Vol. 84 (6) , 685-691
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Recommendations for using TNFα antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for HealthJoint Bone Spine, 2013
- Auto-antibodies to vascular endothelial cadherin in humans: association with autoimmune diseasesLaboratory Investigation, 2013
- Soluble VE‐cadherin in rheumatoid arthritis patients correlates with disease activity: Evidence for tumor necrosis factor α–induced VE‐cadherin cleavageArthritis & Rheumatism, 2011
- TNF-α increases tyrosine phosphorylation of vascular endothelial cadherin and opens the paracellular pathway through fyn activation in human lung endotheliaAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Prevalence of rheumatoid arthritis in France: 2001Annals of the Rheumatic Diseases, 2005
- Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long‐term treatment with anti–tumor necrosis factor α antibodyArthritis Care & Research, 2004
- Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritisArthritis & Rheumatism, 2003
- High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factorsArthritis & Rheumatism, 2001
- Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeabilityBlood, 2001
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995